Related Experiment Video

Updated: May 25, 2026

Invasive Hemodynamic Characterization of the Portal-hypertensive Syndrome in Cirrhotic Rats
09:37

Invasive Hemodynamic Characterization of the Portal-hypertensive Syndrome in Cirrhotic Rats

Published on: August 1, 2018

Portosystemic collaterals are not prerequisites for the development of hepatic encephalopathy in cirrhotic rats

I-Fang Hsin1, Sun-Sang Wang, Hui-Chun Huang

  • 1Division of Gastroenterology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan, ROC.

Journal of the Chinese Medical Association : JCMA
|January 14, 2012
PubMed

Insights

High portosystemic shunting alone does not cause hepatic encephalopathy (HE) in cirrhosis. Liver damage, indicated by elevated liver enzymes and bilirubin, is crucial for HE development, alongside increased tumor necrosis factor-alpha (TNF-α).

Area of Science:

  • Gastroenterology and Hepatology
  • Pathophysiology of Liver Disease
  • Neuroscience Research

Background:

  • Hepatic encephalopathy (HE) in cirrhosis is influenced by liver function and portosystemic collaterals.
  • The relative impact of shunting versus liver damage on HE severity remains unclear.
  • Increased tumor necrosis factor-alpha (TNF-α) in cirrhosis warrants further investigation regarding its role in HE.

Purpose of the Study:

  • To investigate the independent roles of portosystemic shunting and liver damage in the development and severity of hepatic encephalopathy (HE).
  • To evaluate the correlation between specific biomarkers, including TNF-α, and HE-related motor activity deficits.
  • To determine if the degree of portosystemic shunting can predict HE presence and severity.

Main Methods:

  • Induction of portal hypertension via portal vein ligation (PVL) for high shunting without liver damage.
  • Induction of liver cirrhosis via bile duct ligation (BDL) for low shunting with liver damage.
  • Assessment of motor activity, hemodynamic parameters, plasma biomarkers (including TNF-α, AST, total bilirubin), and portosystemic collateral function in rat models.

Main Results:

  • PVL rats (high shunting, no liver damage) showed no significant differences in liver parameters or motor activity compared to controls.
  • BDL rats (low shunting, liver cirrhosis) exhibited elevated TNF-α, AST, and total bilirubin, with reduced motor activity.
  • In BDL rats, higher levels of TNF-α, AST, and total bilirubin were significantly correlated with lower motor activity, while shunt characteristics were not.

Conclusions:

  • A high degree of portosystemic shunting alone is insufficient for the development of hepatic encephalopathy.
  • Liver damage, evidenced by biochemical markers and associated with elevated TNF-α, plays a critical role in HE development.
  • Motor activity deficits in cirrhosis are linked to liver injury markers rather than the degree of shunting.
Abstract

More Related Videos

Heterotopic Auxiliary Rat Liver Transplantation With Flow-regulated Portal Vein Arterialization in Acute Hepatic Failure16:19

Heterotopic Auxiliary Rat Liver Transplantation With Flow-regulated Portal Vein Arterialization in Acute Hepatic Failure

Published on: September 13, 2014

Rat Model of the Associating Liver Partition and Portal Vein Ligation for Staged Hepatectomy (ALPPS) Procedure07:29

Rat Model of the Associating Liver Partition and Portal Vein Ligation for Staged Hepatectomy (ALPPS) Procedure

Published on: August 14, 2017

Related Concept Videos

Hepatic Encephalopathy01:29

Hepatic Encephalopathy

DefinitionHepatic encephalopathy is a reversible neurologic syndrome that results from advanced liver dysfunction or portosystemic shunting. It leads to disturbances in cognition, behavior, and motor function due to the brain’s exposure to gut-derived toxins that the liver fails to detoxify.EtiologyThis condition develops either in the setting of acute fulminant hepatitis or progressively during chronic liver disease, such as cirrhosis and portal hypertension. Portosystemic shunting—including...
Portal Hypertension01:22

Portal Hypertension

Portal hypertension is an increase in blood pressure within the portal venous system. Normally, this pressure is less than 5 mmHg. It is considered clinically significant when it rises above 10 mmHg. At this threshold, complications from altered blood flow and venous congestion emerge.EtiologyPortal hypertension arises from conditions that impede blood flow through the liver. The most common cause is cirrhosis, in which chronic liver injury leads to fibrotic scarring. This fibrosis narrows or...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Cirrhosis II: Pathophysiology01:24

Cirrhosis II: Pathophysiology

Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to structural...
Hepatic Portal System01:21

Hepatic Portal System

The hepatic portal system, a critical part of our circulatory framework, transports nutrient-laden, deoxygenated blood from the gastrointestinal tract and spleen to the liver. This ingenious system plays an indispensable role in maintaining our body's metabolic equilibrium.
At its core, the hepatic portal vein is the result of a confluence of the superior and inferior mesenteric veins along with the splenic vein. Each of these veins has a unique role. The superior mesenteric vein is responsible...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...